Bank of America Increases Ascendis Pharma A/S (NASDAQ:ASND) Price Target to $191.00

Ascendis Pharma A/S (NASDAQ:ASND) had its price target boosted by equities researchers at Bank of America from $175.00 to $191.00 in a research note issued to investors on Monday, Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Bank of America‘s target price suggests a potential upside of 31.82% from the stock’s current price.

ASND has been the subject of several other reports. TD Cowen cut their target price on shares of Ascendis Pharma A/S from $175.00 to $157.00 and set a “buy” rating for the company in a research report on Wednesday, September 4th. Stifel Nicolaus assumed coverage on shares of Ascendis Pharma A/S in a research report on Friday, May 31st. They set a “buy” rating and a $200.00 price objective for the company. Evercore ISI lifted their target price on Ascendis Pharma A/S from $191.00 to $205.00 and gave the company an “outperform” rating in a research report on Tuesday, September 17th. StockNews.com raised Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Thursday, September 5th. Finally, JPMorgan Chase & Co. decreased their price objective on Ascendis Pharma A/S from $174.00 to $165.00 and set an “overweight” rating on the stock in a research note on Wednesday, September 4th. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat, Ascendis Pharma A/S presently has an average rating of “Moderate Buy” and an average price target of $195.00.

Ascendis Pharma A/S Stock Performance

ASND stock opened at $144.89 on Monday. The company has a market cap of $8.44 billion, a price-to-earnings ratio of -15.08 and a beta of 0.63. The business’s 50-day moving average is $133.83 and its two-hundred day moving average is $136.49. Ascendis Pharma A/S has a fifty-two week low of $85.29 and a fifty-two week high of $161.00.

Hedge Funds Weigh In On Ascendis Pharma A/S

Hedge funds have recently modified their holdings of the stock. Private Ocean LLC purchased a new position in Ascendis Pharma A/S during the first quarter valued at $36,000. Quadrant Capital Group LLC increased its holdings in shares of Ascendis Pharma A/S by 90.4% in the fourth quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 151 shares during the last quarter. EverSource Wealth Advisors LLC lifted its position in shares of Ascendis Pharma A/S by 37.6% in the fourth quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company’s stock worth $42,000 after buying an additional 91 shares in the last quarter. GAMMA Investing LLC boosted its stake in Ascendis Pharma A/S by 52.0% during the first quarter. GAMMA Investing LLC now owns 298 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 102 shares during the last quarter. Finally, Barometer Capital Management Inc. purchased a new position in Ascendis Pharma A/S during the 4th quarter valued at approximately $126,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.